{"id":1397,"date":"2017-11-15T00:00:00","date_gmt":"2017-11-14T23:00:00","guid":{"rendered":"https:\/\/www.ship2b.org\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health"},"modified":"2025-02-08T01:10:05","modified_gmt":"2025-02-08T00:10:05","slug":"glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health","status":"publish","type":"post","link":"https:\/\/www.ship2b.org\/en\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/","title":{"rendered":"GlyCardial Diagnostics cierra su primera ronda de inversi\u00f3n con 2,4M ? | #LABTech4Health"},"content":{"rendered":"\n<p><strong>GlyCardial Diagnostics<\/strong>, spin-off de l&#8217;Institut Catal\u00e0 de Ci\u00e8ncies Cardiovasculars y proyecto seleccionado en el LAB de inversi\u00f3n y aceleraci\u00f3n&nbsp;<a href=\"https:\/\/ship2b.org\/tech4health\"><strong>Tech4Health<\/strong><\/a>,&nbsp;<strong>consigue 2,4 millones de euros en su primera&nbsp;ronda de inversi\u00f3n<\/strong>. GlyCardial Diagnostics&nbsp;ha desarrollado un biomarcador innovador que, no solo permitir\u00e1 detectar previamente enfermedades cardiovasculares, sino que tambi\u00e9n identificar\u00e1 a pacientes con riesgo de reincidencia.<\/p>\n\n\n\n<p>La ronda ha sido liderada por <strong>Caixa Capita Risc<\/strong>, partner cofundador del LAB Tech4Health, y en la que tambi\u00e9n ha participado el fondo de inversi\u00f3n <strong>HealthEquity SCR<\/strong>, promovido por el <strong>Col\u00b7legi Oficial de Metges de Barcelona<\/strong>, entidad colaboradora del LAB.<\/p>\n\n\n\n<p>La empresa, constituida el pasado septiembre por cuatro investigadoras, espera que en unos tres o cuatro a\u00f1os el test est\u00e9 listo para salir al mercado y utilizarse con un fin m\u00e9dico. ?<em>Este proceso necesita mucha&nbsp;<strong>financiaci\u00f3n<\/strong><\/em>?, asegura <strong>Judith Cubedo<\/strong>, consejera delegada de&nbsp;<strong>GlyCardial Diagnostics<\/strong>.&nbsp;Por su parte <strong>Maite Fibla<\/strong>, cofundadora de <strong>Ship2b<\/strong> y directora del <strong>Lab Tech4Health<\/strong> asegura que ?<em>es un proyecto con mucho potencial en el que se est\u00e1 trabajando continuamente para conseguir la validaci\u00f3n m\u00e9dica que permita salir al mercado. Desde Ship2B estamos seguros de que ser\u00e1 un caso de \u00e9xito?<\/em>.<\/p>\n\n\n\n<p>Con ese dinero, se seguir\u00e1 trabajando en la investigaci\u00f3n para desarrollar una prueba que detecte la isquemia card\u00edaca (<strong>falta de riego sangu\u00edneo<\/strong>) antes de que sea irreversible. Esta afectaci\u00f3n, si persiste, podr\u00eda provocar&nbsp;<strong>infartos, anginas en el pecho y otras enfermedades del coraz\u00f3n<\/strong>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><a href=\"https:\/\/ship2b.org\/tech4health\/\"><strong>Lab Tech4Health<\/strong><\/a><\/h4>\n\n\n\n<p><strong>Ship2B, Palex, DKV, Esteve, Medichem, Reig Jofre, Nae, Caixa Capital Risc y Sant Joan de D\u00e9u son los partners cofundadores del LAB Tech4Health, la plataforma de inversi\u00f3n y aceleraci\u00f3n para startups del sector salud <\/strong>que quieren ir m\u00e1s all\u00e1 de la rentabilidad econ\u00f3mica, persiguiendo impactar positivamente en nuestra sociedad a trav\u00e9s de proyectos disruptivos y altamente rentables.<\/p>\n\n\n\n<p>En el marco del programa se han acelerado 17 startups, entre las que destacan MJN Neuroserveis, Visualfy o Cebiotex, proyectos que han participado en el LAB en las anteriores ediciones y han sido invertidas por B-Fund, veh\u00edculo de inversi\u00f3n de Ship2B, y la comunidad de inversi\u00f3n de impacto con la que cuenta la Fundaci\u00f3n.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlyCardial Diagnostics, spin-off de l&#8217;Institut Catal\u00e0 de Ci\u00e8ncies Cardiovasculars y proyecto seleccionado en el LAB de inversi\u00f3n y aceleraci\u00f3n&nbsp;Tech4Health,&nbsp;consigue 2,4 millones de euros en su primera&nbsp;ronda de inversi\u00f3n. GlyCardial Diagnostics&nbsp;ha desarrollado un biomarcador innovador que, no solo permitir\u00e1 detectar previamente enfermedades cardiovasculares, sino que tambi\u00e9n identificar\u00e1 a pacientes con riesgo de reincidencia. La ronda ha &hellip; <a href=\"https:\/\/www.ship2b.org\/en\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/\">Read more<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[23,27,191],"tags":[184,186],"class_list":["post-1397","post","type-post","status-publish","format-standard","hentry","category-inversion-de-impacto","category-aceleracion","category-salud-y-calidad-de-vida","tag-s2b-tech4social","tag-s2b-tech4health"],"acf":[],"yoast_head":"<title>GlyCardial Diagnostics cierra su primera ronda de inversi\u00f3n con 2,4M ? | #LABTech4Health - Ship2B Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GlyCardial Diagnostics cierra su primera ronda de inversi\u00f3n con 2,4M ? | #LABTech4Health - Ship2B Foundation\" \/>\n<meta property=\"og:description\" content=\"GlyCardial Diagnostics, spin-off de l&#8217;Institut Catal\u00e0 de Ci\u00e8ncies Cardiovasculars y proyecto seleccionado en el LAB de inversi\u00f3n y aceleraci\u00f3n&nbsp;Tech4Health,&nbsp;consigue 2,4 millones de euros en su primera&nbsp;ronda de inversi\u00f3n. GlyCardial Diagnostics&nbsp;ha desarrollado un biomarcador innovador que, no solo permitir\u00e1 detectar previamente enfermedades cardiovasculares, sino que tambi\u00e9n identificar\u00e1 a pacientes con riesgo de reincidencia. La ronda ha &hellip; Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/\" \/>\n<meta property=\"og:site_name\" content=\"Ship2B Foundation\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-14T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-08T00:10:05+00:00\" \/>\n<meta name=\"author\" content=\"monolitdigital\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"monolitdigital\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/\",\"url\":\"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/\",\"name\":\"GlyCardial Diagnostics cierra su primera ronda de inversi\u00f3n con 2,4M ? | #LABTech4Health - Ship2B Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.ship2b.org\/#website\"},\"datePublished\":\"2017-11-14T23:00:00+00:00\",\"dateModified\":\"2025-02-08T00:10:05+00:00\",\"author\":{\"@id\":\"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/www.ship2b.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GlyCardial Diagnostics cierra su primera ronda de inversi\u00f3n con 2,4M ? | #LABTech4Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ship2b.org\/#website\",\"url\":\"https:\/\/www.ship2b.org\/\",\"name\":\"Ship2B Foundation\",\"description\":\"Adventurers for a better world\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ship2b.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb\",\"name\":\"monolitdigital\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ship2b.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g\",\"caption\":\"monolitdigital\"},\"url\":\"https:\/\/www.ship2b.org\/en\/actualidad\/author\/monolitdigital\/\"}]}<\/script>","yoast_head_json":{"title":"GlyCardial Diagnostics cierra su primera ronda de inversi\u00f3n con 2,4M ? | #LABTech4Health - Ship2B Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/","og_locale":"en_US","og_type":"article","og_title":"GlyCardial Diagnostics cierra su primera ronda de inversi\u00f3n con 2,4M ? | #LABTech4Health - Ship2B Foundation","og_description":"GlyCardial Diagnostics, spin-off de l&#8217;Institut Catal\u00e0 de Ci\u00e8ncies Cardiovasculars y proyecto seleccionado en el LAB de inversi\u00f3n y aceleraci\u00f3n&nbsp;Tech4Health,&nbsp;consigue 2,4 millones de euros en su primera&nbsp;ronda de inversi\u00f3n. GlyCardial Diagnostics&nbsp;ha desarrollado un biomarcador innovador que, no solo permitir\u00e1 detectar previamente enfermedades cardiovasculares, sino que tambi\u00e9n identificar\u00e1 a pacientes con riesgo de reincidencia. La ronda ha &hellip; Read more","og_url":"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/","og_site_name":"Ship2B Foundation","article_published_time":"2017-11-14T23:00:00+00:00","article_modified_time":"2025-02-08T00:10:05+00:00","author":"monolitdigital","twitter_card":"summary_large_image","twitter_misc":{"Written by":"monolitdigital","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/","url":"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/","name":"GlyCardial Diagnostics cierra su primera ronda de inversi\u00f3n con 2,4M ? | #LABTech4Health - Ship2B Foundation","isPartOf":{"@id":"https:\/\/www.ship2b.org\/#website"},"datePublished":"2017-11-14T23:00:00+00:00","dateModified":"2025-02-08T00:10:05+00:00","author":{"@id":"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb"},"breadcrumb":{"@id":"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ship2b.org\/actualidad\/glycardial-diagnostics-cierra-su-primera-ronda-de-inversion-con-24m-e-labtech4health\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.ship2b.org\/en\/"},{"@type":"ListItem","position":2,"name":"GlyCardial Diagnostics cierra su primera ronda de inversi\u00f3n con 2,4M ? | #LABTech4Health"}]},{"@type":"WebSite","@id":"https:\/\/www.ship2b.org\/#website","url":"https:\/\/www.ship2b.org\/","name":"Ship2B Foundation","description":"Adventurers for a better world","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ship2b.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb","name":"monolitdigital","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ship2b.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g","caption":"monolitdigital"},"url":"https:\/\/www.ship2b.org\/en\/actualidad\/author\/monolitdigital\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts\/1397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/comments?post=1397"}],"version-history":[{"count":3,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts\/1397\/revisions"}],"predecessor-version":[{"id":15209,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts\/1397\/revisions\/15209"}],"wp:attachment":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/media?parent=1397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/categories?post=1397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/tags?post=1397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}